Navigating the drug development pipeline

The expansion in the development and manufacturing of highly potent active pharmaceutical ingredients (HPAPIs) and complex active pharmaceutical ingredients (APIs) has grown tremendously as demands in healthcare to bring newer therapies to market quicker increase. Selecting a technique that is both safe and efficacious is key when handling and producing these newer therapies at accelerated rates.

Lonza’s Charles Johnson and David K. Lyon, PhD, highlight common concerns associated with the handling of HPAPIs and share insight into selecting the right method for the job.

Charles Johnson
Senior Director,
Commercial Development Lonza

David K. Lyon, PhD
Sr Fellow,
Global Research Lonza